Timeline of COVID-19 Vaccines and Treatment


November 16 Moderna announces that the interim results of their Covid-19 vaccine candidate Phase III clinical trial have met their primary efficacy endpoint (94.5% (p <0.0001)). 95 participants contracted Covid-19 out of 30,000 participants. 1)

November 18 Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints. 95% effective against COVID-19 beginning 28 days after the first dose. 2)

December 2 Pfizer and BioNTech Achieve First Authorization in the World for a Vaccine to Combat COVID-19. The Medicines & Healthcare Products Regulatory Agency (MHRA) in the U.K. has granted a temporary authorization for emergency use for their COVID-19 mRNA vaccine (BNT162b2).3)

December 11 Pfizer receives an Emergency Use Authorization in the USA for it's Covid-19 vaccine. 4)

December 18 Moderna receives an Emergency Use Authorization in the USA for it's Covid-19 vaccine. 5)


December 09 US FDA Expands Eligibility for Pfizer-BioNTech COVID-19 Booster Dose to 16- and 17-Year-Olds.6)

October 29 US FDA Authorizes COVID-19 Vaccine in Children 5 through 11. 7)

September 22 US FDA Authorizes Booster Dose of Pfizer-BioNTech COVID-19 Vaccine for Those Older than 65 and those at High Risk for Sever Covid-19.8)

August 12 US FDA Authorizes Booster Dose for Immunocompromised People9)

May 10 US FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Adolescents age 12-15.10)

April 23 USA FDA and CDC Lift the Safety Pause on the Johnson & Johnson (Janssen) COVID-19 Vaccine.11)

April 13 U.S. CDC and FDA recommend a pause on the Johnson & Johnson (Janssen) vaccine due to 6 cases cerebral venous sinus thrombosis (CVST).12)

February 27 US FDA issues an emergency use authorization (EUA) for the Janssen COVID-19 Vaccine to be distributed in the U.S. for use in individuals 18 years of age and older. 13)


January 3 FDA expands Pfizer-BioNTech COVID-19 Vaccine EUA to include the use of a single booster dose in children 12 through 15 years of age; shorten the time between the completion of primary vaccination of the Pfizer-BioNTech COVID-19 Vaccine and a booster dose to at least five months, and allow for a third primary series dose for certain immunocompromised children 5 through 11 years of age.14)